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Objectives. Our aims were 1) to assess whether oral pirenzepine 
could increase indexes of cardiac vagal activity in postinfarction 
patients, and 2) to compare the effects of this agent with those of 
transdermal scopolamine. 
Background. Depression of vagal tone and reflexes predicts a 
poor arrhythmic outcome after myocardial infarction. Interven- 
tions for shifting the sympathovagal balance toward vagal domi- 
nance are now of increased clinical interest. Intravenous pirenz- 
epine increases RR interval variability in normal volunteers, a 
finding that could have therapeutic implications if confirmed in 
postinfarction patients after oral administration of the drug. 
Methods. In a single-blind placebo-controlled crossover trial, 
short-term RR interval variability and baroreceptor reflex sensi- 
tivity were evaluated in 20 patients an average of 19 -+ 6 days after 
infarction. Analysis was performed during control conditions and 
during administration of placebo, oral pirenzepine and transder- 
real scopolamine. 
Results. Compared with placebo, at a dose of 25 mg twice daily, 
pirenzepine significantly increased all time and frequency domain 
measures of RR interval variability and augmented baroreceptor 
reflex sensitivity by 60% (mean -+ 1 SD 10.4 -+ 5.9 vs. 6.5 -+ 
3.2 ms/ram Hg, p = 0.0007). Pirenzepine and scopolamine showed 
a similar vagomimetic effect, but the overall incidence of adverse 
effects was lower with pirenzepine (1 [5%] of 20 vs. 10 [50%] of 
20). 
Conclusions. In patients with a recent myocardial infarction, 
oral pirenzepine proved equal to transdermal scopolamine in 
significantly increasing indexes of cardiac vagal activity. These 
data suggest hat oral pirenzepine may have a therapeutic poten- 
tial for preventing malignant ventricular arrhythmias after infarc- 
tion. 
(J Am Coll Cardiol 1995;25:915-21) 
A strong correlation between impaired autonomic function 
and poor arrhythmic outcome after acute myocardial infarc- 
tion has been found in several clinical studies (1-5). Therefore, 
manipulation of cardiac sympathovagal interaction may have 
an important herapeutic potential in preventing life-threatening 
ventricular arrhythmias after infarction. In one strategy for using 
this potential, sympathetic activity is antagonized by beta- 
adrenergic blockade, and the efficacy of beta-blockers in 
reducing the risk of sudden death after myocardial infarction is 
well known (6). Experimental studies (7,8) suggest hat an 
alternative strategy may be to increase parasympathetic activ- 
ity. In humans, atropine is known to induce bradycardia (as a 
"paradoxic" vagomimetic effect) at low doses and to result in 
the expected heart rate increase (as the typical antimuscarinic 
effect) at higher doses (9). Recent studies (10-16) showed that 
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low doses of transdermal scopolamine may induce a significant 
increase in tonic and reflex cardiac vagal outflow in normal 
subjects, survivors of myocardial infarction and patients with 
congestive heart failure. Because pharmacologic vagal stimu- 
lation may represent a novel therapeutic approach for prevent- 
ing malignant ventricular arrhythmias after acute myocardial 
infarction, further investigation of the vagomimetic power of 
different drugs is desirable. Low doses of intravenous pirenz- 
epine, an antimuscarinic agent widely used for peptic ulcer 
therapy, were found to increase the standard eviation (SD) of 
the RR intervals by 58% in six normal volunteers (9). This 
finding could have therapeutic mplications if the results are 
confirmed in postinfarction patients after oral administration 
of the drug. 
The aims of the present study were 1) to assess whether low 
doses of oral pirenzepine could induce a sustained increase in 
cardiac vagal outflow after acute myocardial infarction, and 
2) to compare the autonomic effects and tolerability of oral 
pirenzepine with those of transdermal scopolamine. 
Methods  
Study design. The present study was conducted in two 
sequential phases to determine 1) the oral dose of pirenzepine 
required to produce the maximal parasympathomimetic ffect, 
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Table 1. Effects of Increasing Doses of Oral Pirenzepine on Baroreceptor Reflex Sensitivity in Eight 
Postinfarction Patients 
Baroreceptor  Reflex Sensitivity (ms/ram Hg) 
Oral  Pirenzepine 
Control 
Pt No. Period 12.5 mg BID 25 mg BID 37.5 mg BID 50 mg BID 
1 3.6 3.3 4.8 5.1 6.3 
2 11.3 21.0" 12.4 - -  - -  
3 3.3 7.2 10.1" 6.6 - -  
4 11.0 11.0 15.4" 12.8 - -  
5 6.5 0.8 - -  - -  - -  
6 3.0 6.1 4.2 5.3 6.5 
7 4.4 7.5 8.8* 5.5 - -  
8 3.4 5.1 8.4* 4.5 - -  
Mean 5.8 7.7 9.2 6.6 - -  
SD 3.5 6.1 4.0 3.1 - -  
*Baroreceptor reflex sensitivity increase >4 ms/mm Hg from control value. BID - twice daily; Pt = patient; - -  = 
test not performed. 
and 2) the increase of tonic and reflex vagal cardiac activity 
induced by pirenzepine and scopolamine in postinfarction 
patients. 
In phase 1 we determined the effect of different doses of 
oral pirenzepine on baroreceptor reflex sensitivity in eight 
consecutive patients. All patients were men (mean age ___ SD 
54 _+ 10 years, mean left ventricular ejection fraction 51 _+ 
8%). Six patients (75%) had a Q-wave infarction, three (37%) 
an anterior wall infarction and five (62%) an inferior wall 
infarction. Four patients (50%) underwent thrombolysis in the 
acute phase of infarction. 
After giving informed written consent to the study, all 
patients underwent a baseline evaluation of baroreceptor 
reflex sensitivity. Then, the titration phase was started and the 
patients were given increasing doses of oral pirenzepine (Gas- 
trozepin, Boehringer Ingelheim) every 2 days until a significant 
increase in baroreceptor reflex sensitivity occurred (Table 1). 
As we (13) have described elsewhere, a baroreceptor reflex 
sensitivity increase >4 ms/ram Hg from baseline value was 
considered a true change. Therefore, baroreceptor reflex sen- 
sitivity was reassessed after 2 days of therapy for each oral dose 
tested. If baroreceptor reflex sensitivity increased by >4 
ms/ram Hg, the patient was considered a responder and that 
dose of pirenzepine was defined as effective. All patients who 
responded also received the subsequent dose to exclude the 
possibility of a further increase in vagal activity. 
From December 1993 to February 1994, 23 patients who 
survived an acute myocardial infarction were admitted to our 
institute for cardiac rehabilitation. Of these, 20 were eligible 
for the present investigation and underwent phase 2 of the 
study after giving informed written consent. Eighteen patients 
were men and two were women (mean age 56 + 8 years, mean 
left ventricular ejection fraction 48 + 6%). Sixteen patients 
(80%) had a Q wave infarction; 10 (50%) underwent throm- 
bolysis in the acute phase of infarction. Eight patients (40%) 
had an anterior, 11 (55%) an inferior and 1 patient (5%) a 
lateral wall myocardial infarction. Three other patients were 
excluded from the study because of insulin-dependent diabetes 
mellitus. The other exclusion criteria were age >70 years; 
flutter or atrial fibrillation (or both); frequent atrial or ventric- 
ular arrhythmia that made analysis of sinus cycle impossible; 
abnormal sinus node function; atrioventricular block; ventric- 
ular paced rhythm; blood pressure >160/90 mm Hg with 
diuretic agents or angiotensin-converting e zyme inhibitors (or 
both); postinfarction unstable angina; heart failure unrespon- 
sive to administration ofangiotensin-converting e zyme inhib- 
itors and diuretic agents. All patients were studied between 10 
and 36 days (average 19 -4- 6) after infarction, and no patient 
was receiving beta-adrenergic blocking agents, calcium channel 
antagonists, digitalis or antiarrhythmic drugs at the time of the 
investigation. Diuretic agents, angiotensin-converting e zyme 
inhibitors and nitrates were allowed, if needed, to control 
blood pressure, pulmonary congestion and myocardial isch- 
emia. Eight patients received angiotensin-converting e zyme 
inhibitor therapy, eight received nitrates and one patient 
received iuretic agents. No change in drug prescription was 
allowed during the investigation. 
The study protocol consisted of the assessment of heart rate 
variability and baroreceptor reflex sensitivity in a control 
period and during administration of placebo, pirenzepine and 
scopolamine. The study was designed as a single-blind, place- 
bo-controlled, crossover trial. After a baseline evaluation of 
both baroreceptor reflex sensitivity and heart rate variability, 
all patients received each of three treatments in random order: 
placebo (one placebo patch behind one ear plus one placebo 
tablet wice daily), pirenzepine (one placebo patch behind one 
ear plus one pirenzepine tablet twice daily) and scopolamine 
(one patch of transdermal scopolamine behind one ear plus 
one placebo tablet wice daily). Each treatment was given for 3 
days, separated by washout periods of 2 days, and heart rate 
variability and baroreceptor reflex sensitivity were always 
assessed after 48 h of therapy. During pirenzepine treatment, 
all patients were given oral pirenzepine at the dose of 25 mg 
twice daily, 30 min after breakfast and dinner, respectively. The 
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therapeutic system (Transcop, Recordati) used delivers a low 
dose of scopolamine (0.5 mg daily) at a continuous rate over 3 
days. The patients were informed about the possible side 
effects induced by vagal stimulation and asked to report hem 
on a questionnaire at the end of the placebo, pirenzepine and 
scopolamine treatment periods. The protocol was approved by 
the committee on human investigation at our institution. 
Heart rate variability assessment. During each treatment 
period, heart rate variability was assessed at the same time of 
day, ->3 h after a light meal. Throughout the study, smoking 
and caffeine consumption were prohibited. The patients were 
studied at supine rest in a quiet, temperature-controlled room 
and were asked to relax and to avoid talking and sleeping. The 
recording was started after 10 rain of acclimatization a d lasted 
20 rain. Our heart rate variability analysis ystem consists of a 
conventional bedside monitor (Supermon 7210, Kontron In- 
struments), providing an electrocardiographic (ECG) signal 
and a respiratory signal obtained by measuring the changing 
impedance between two leads, and a Compaq 486 computer 
with 12-bit analog/digital interface. Custom-made software 
(R. Colombo, PhD, Veruno, Italy) was used for analysis of 
heart rate variability. The ECG and respiratory signals were 
acquired at a sampling rate of 1 kHz and 250 Hz, respectively. 
A preprocessing phase removed artifacts in the acquired time 
series and replaced them with the expected values by linear 
interpolation between two preceding and two successive inter- 
beat intervals. An off-line analysis was performed on detren- 
dized, 10-rain stationary sections of normal RR intervals. A 
reverse arrangements test (17) was used to verify stationarity 
and the significance l vel was set at p value of 0.05. 
Both time domain and power spectral analyses were per- 
formed. Time domain variables considered were the mean RR 
interval and its SD, the mean squared successive difference 
interval and the percent of sinus cycles differing from the 
preceding cycle by >50 ms. The power spectral density of the 
time series was then evaluated by an autoregressive method. 
The algorithm used to identify the autoregressive model was 
the Batch Least Square method, by means of Levinson-Durbin 
recursion usually stopped at the 20th order. The Anderson test 
and the Portmanteau test were used to check the validity of the 
model, and the order of the model was chosen by minimization 
of the Akaike Information Criterion figure of merit. A spectral 
decomposition method was then applied, and the power and 
the center frequency of each spectral component were evalu- 
ated; the coherence function between heart rate and respira- 
tion variabilities was also analyzed. The absolute power of the 
spectral components was expressed in ms 2. 
The time series was created as a function of heart beats; this 
frequency was converted into hertz equivalent (indicated as 
Hz) by dividing it by the mean RR interval. Two main 
components in the spectra of heart rate variability were 
identified: 1) a high frequency component (from 0.18 to 
0.35 Hz on average, with a peak centered at 0.28 Hz), and 2) a 
low frequency component (from 0.03 to 0.15 Hz on average, 
with a peak centered at 0.10 Hz). A very low frequency peak 
was generally not revealed by the spectral decomposition 
method; therefore, the very low frequency power was calcu- 
lated by integrating the frequency band (from 0.002 to 0.03 Hz) 
under the spectral curve. The total power (power in the band 
up to 0.50 Hz) was also calculated. The principles of our 
software have been described in more detail elsewhere (18). 
Baroreceptor reflex sensitivity assessment. Baroreceptor 
reflex sensitivity was assessed shortly after heart rate variability 
testing, according to a method previously described (4,19). 
Blood pressure was continuously monitored noninvasively by 
an infrared igital plethysmograph (Finapres 2300, Ohmeda). 
This signal and one ECG lead were digitized and fed into a 
Compaq 386 computer with custom-made software (G.D. 
Pinna, PhD, Montescano, Italy) for analysis of baroreceptor 
reflexes. After a 10 rain rest period, phenylephrine hydrochlo- 
ride (initial dose 2 p~g/kg body weight) was injected into an 
antecubital vein to obtain an increase in systolic arterial 
pressure >15 and <40 mm Hg. Systolic blood pressure and RR 
intervals were calculated as increments with respect o baseline 
conditions. The RR intervals were plotted against he preced- 
ing arterial pulse, and a linear regression analysis was per- 
formed for points included between the beginning and the end 
of the first significant increase in systolic arterial pressure. Only 
regression lines with a correlation coefficient >0.70 were 
accepted for analysis. A final slope was obtained by calculating 
the mean value of three or more determinations. This value 
was then considered to represent he baroreceptor reflex 
sensitivity (ms/mm Hg). 
With a Marquette CENTRA system, a standard 12-lead 
ECG was recorded in all patients before the baroreceptor 
reflex sensitivity analysis, and automatic measurements of the 
PR interval, QRS complex duration and QT interval corrected 
for heart rate were available. 
Echocardiographic studies. A two-dimensional echocar- 
diogram was obtained by using a Ving Med CFM 750 unit 15 _+ 
6 days after infarction; left ventricular ejection fraction was 
obtained by the area-length formula. 
Statistical analysis. Continuous variables were expressed 
as mean value + 1 SD and tested for normal distribution with 
the Shapiro and Wilk W statistic (20). For normal distributions 
(mean RR interval and its SD, PR interval and QT interval 
corrected for heart rate), the overall difference among mean 
values in the four study periods (control, placebo, pirenzepine, 
scopolamine) was analyzed by analysis of variance for repeated 
measures; for nonnormal distributions (mean squared succes- 
sive difference interval, percent of sinus cycles differing from 
the preceding cycle by >50 ms, total power, high frequency, 
low frequency and very low frequency power, ratio of low to 
high frequency power and QRS complex duration), the four 
periods were compared by using the Friedman two-way anal- 
ysis of variance. A two-tailed p value < 0.05 was required for 
statistical significance. In a subsequent direct comparison, the 
t test for paired samples or the Wilcoxon signed rank test was 
used. The following comparisons were performed: control 
versus placebo, pirenzepine versus placebo, scopolamine ver- 
sus placebo, pirenzepine versus scopolamine. The limit for 
significance was set at p < 0.012, according to the Bonferroni 
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Table 2. Time Domain Measures ofHeart Rate Variability Calculated From 10-Min Intervals During 
Control, Placebo, Pirenzepine and Scopolamine P riods in 20 Postinfarction Patients 
Study Period 
Pirenzepine Scopolamine 
Interval Control Placebo (25 mg BID) (0.5 mg daily) p Value 
Mean RR (ms) 916 _+ 142 907 : 138 970 + 137 997 _+ 137 < 0.0001 
SD (ms) 3l + 15 31 -+ 14 46 + 18 41 _+ 16 < 0.0001 
MSSD (ms)* 19 + 13 16 -+ 10 30 : 17 31 + 19 < 0.0001 
PNN50 (% of beats)* 2.2 _+ 4.9 1.7 _+ 3.8 5.8 _+ 7.(I 5.9 _+ 7.0 < 0.0001 
Data are presented as mean value _+ 1 SD. The four groups are compared using analysis of variance for repeated 
measures or (*) Friedman two-way analysis of variance. BID = twice daily; MSSD - mean squared successive difference 
interval; PNN50 = percent of sinus cycles differing from the preceding cycle by >50 ms; SD = standard eviation of 
normal RR intervals. 
adjustment. All of these analyses were performed by the 
BMDP Statistical Software (1990 version). 
Resu l ts  
Dose-ranging studies. The effects of increasing doses of 
oral pirenzepine on baroreceptor reflex sensitivity are illus- 
trated in Table 1. Of eight patients studied, five (62%) showed 
a significant increase in baroreceptor reflex sensitivity and were 
considered responders topirenzepine; four (80%) of these five 
responded at a dose of 25 mg twice daily. In all patients who 
responded, administration f a pirenzepine dose higher than 
the effective dose did not induce a further increase in barore- 
ceptor reflex sensitivity. During treatment with 25 mg twice 
daily, pirenzepine increased baroreceptor reflex sensitivity by 
59%, and the baroreceptor reflex sensitivity was significantly 
higher than during control conditions (9.2 + 4.0 vs. 5.8 + 
3.5 ms/mm Hg, p = 0.007). This dose was selected for phase 2 
of the study. 
Effects of oral pirenzepine and transdermal scopolamine 
on time domain measures of heart rate variability. The effects 
of placebo, pirenzepine and scopolamine on time domain 
measures of heart rate variability are shown in Table 2. 
Statistical analysis revealed a significant (p < 0.0001) differ- 
ence among the four study periods. There was no significant 
difference in any of the variables between placebo and control 
conditions or between pirenzepine and scopolamine treat- 
ments. During pirenzepine administration, all time domain 
measures ofheart rate variability were significantly higher than 
during placebo administration: The mean RR interval (p = 
0.0001) and its SD (p = 0.0002) increased by 7% and by 48%, 
respectively; the mean squared successive difference interval 
increased by 87% (p < 0.0001), and the percent of sinus cycles 
differing from the preceding cycle by >50 ms increased by 
241% (p = 0.0006). A similar result was obtained uring 
scopolamine administration: Compared with the placebo pe- 
riod, the mean RR interval (p < 0.0001) and its SD (p = 0.005) 
increased by 10% and by 32%, respectively; the mean squared 
successive difference interval increased by 94% (p = 0.0002), 
and the percent of sinus cycles differing from the preceding 
cycle by >50 ms increased by 247% (p = 0.004). 
Effects of oral pirenzepine and transdermal scopolamine 
on frequency domain measures of heart rate variability. In 
one or more conditions, three patients howed a high coher- 
ence between heart rate and respiration variabilities in the low 
frequency band of the spectrum. We therefore analyzed fre- 
quency domain measures of heart period variability in 17 
patients (Table 3) and found significant differences among the 
four study periods in total power (p < 0.0001) and in high (p < 
0.0001), low (p = 0.007) and very low (p = 0.005) frequency 
power. Conversely, the ratio of low to high frequency power 
did not show a significant difference. There was no difference 
Table 3. Frequency Domain Measures ofHeart Rate Variability Calculated From 10-Min Intervals During 
Control, Placebo, Pirenzepine and Scopolamine P riods in 17 Postinfarction Patients 
Control Placebo 
Stud}, Period 
Pirenzepine Scopolamine 
(25 mg BID) (0.5 mg daily) p Value 
Total power (ms 2) 984.17 _+ 1037.80 1,(/t)6.09 _+747.42 2,129.26 _+1,563.69 1,734.25 _+1,357.89 < 0.0001 
HF (ms 2) 120.96 + 252.30 68.50 _+ 105.14 256.17 _+ 363.91 251.00 _+ 351.15 < 0.000l 
LF (ms 2) 140.37 _+ 246.12 140.09 _+ 16(I.84 336.71 + 387.15 382.84 _+ 502.87 0.007 
VLF (ms 2) 477.06 _+ 423.43 524.71 _+ 402.05 952.76 _+ 793.11 664.68 _+ 512.31 t).005 
LF/HF ratio 2.09 + 2.20 3.56 -+ 3.62 1.96 -- 1.78 5.66 -+ 9.(13 0.43 
Data are presented as mean value + 1 SD. The four groups are compared using Friedman two-way analysis of 
variance. BID = twice daily; HF, LF and VLF, respectively, - high frequency, low frequency and very low frequency 
spectral components of RR interval variability. 
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Figure l .  Effects of placebo, pirenzepine and scopolamine treatment 
on baroreceptor reflex sensitivity. Pirenzepine (p = 0.0007) and 
scopolamine (p - 0.002) significantly increased baroreceptor reflex 
sensitivity compared with values during placebo administration. Bars 
represent mean value + 1 SD. 
Effects of oral pirenzepine and transdermal scopolamine 
on standard 12-lead ECG. Results of the statistical analysis 
for the PR interval, QRS complex duration and QT interval 
corrected for heart rate are illustrated in Table 4. The standard 
12-lead ECG disclosed no significant difference in any of the 
analyzed variables. 
Adverse effects of oral pirenzepine and transdermal scopol- 
amine. The overall incidence of adverse effects was lower 
during treatment with pirenzepine than with scopolamine 
(1 [5%] of 20 vs. 10 [50%] of 20). During scopolamine 
administration, eight patients reported ry mouth, two drows- 
iness and two others blurred vision and nausea, respectively. 
Conversely, only one patient reported nausea during pirenz- 
epine treatment. No patients required withdrawal of vagomi- 
tactic drugs before termination of the study. 
in any of the variables between placebo and baseline condi- 
tions or between pirenzepine and scopolamine treatments. 
Compared with placebo, pirenzepine increased the total power 
by 112% (p = 0.002), the high frequency power by 274% (p < 
0.0001) and the very low frequency power by 81% (p = 0.009), 
respectively. A trend toward a difference was noted for the low 
frequency component (140% increase; p = 0.02). Compared 
with placebo, transdermal scopolamine significantly increased 
high (p -- 0.004) and low (p = 0.009) frequency power by 266% 
and by 173%, respectively. It also increased total power by 
72% (statistical analysis howed a borderline p value: p = 
0.019). Very low frequency power did not differ significantly 
between the scopolamine and placebo periods. 
Effects of oral pirenzepine and transdermal scopolamine 
on baroreceptor eflex sensitivity. Statistical analysis for the 
baroreceptor reflex sensitivity disclosed a significant (p < 
0.0001) difference among the four study periods (Fig. 1). As 
with the other variables analyzed, no difference was found 
between control and placebo conditions (5.8 + 3.4 vs. 6.5 _+ 
3.2 ms/ram Hg, p = 0.19) or between pirenzepine and scopol- 
amine treatments (10.4 _+ 5.9 vs. 10.4 _+ 6.8 ms/mm Hg, p = 
0.79). Compared with placebo, both pirenzepine (10.4 +_ 5.9 vs. 
6.5 _+ 3.2 ms/ram Hg, p = 0.0007) and scopolamine (10.4 _+ 6.8 
vs. 6.5 +_ 3.2 ms/ram Hg, p = 0.002) significantly increased 
baroreceptor reflex sensitivity by 60%. 
Discuss ion  
The present investigation shows that low doses of oral 
pirenzepine may induce a significant increase in heart rate 
variability and baroreceptor reflex sensitivity in patients with a 
recent myocardial infarction. The data suggest that the effects 
of oral pirenzepine on cardiac sympathovagal interaction are 
similar to those induced by transdermal scopolamine, which 
has improved measures of both tonic and reflex cardiac vagal 
outflow after myocardial infarction (12-15). However, the 
incidence of adverse ffects was lower during treatment with 
pirenzepine than with scopolamine. Because indexes of cardiac 
vagal activity are shifted toward values associated with a lower 
risk of death, especially sudden death (1-5), pharmacologic 
vagal stimulation by means of oral pirenzepine could have 
clinical relevance in preventing postinfarction arrhythmic 
events. 
Cardiac autonomic function and ventricular electrical in- 
stability. Malignant ventricular arrhythmias nd sudden death 
remain major problems after myocardial infarction. A fatal 
ventricular arrhythmia s a multifactorial event. As Myerburg 
et al. (21) suggest, its occurrence is preconditioned by a 
structural bnormality hat is modulated by functional factors 
such as neurophysiologic interactions and ischemia that can 
convert chronic ambient arrhythmias into triggering events for 
potentially fatal ventricular tachyeardia and fibrillation (21). 
Table 4. Standard 12-Lead Electrocardiogram During Control, Placebo, Pirenzepine and Scopolamine 
Periods in 20 Postinfaretion Patients 
Study Period 
Control Placebo Pirenzepine Scopolamine p Value 
PR interval (ms) 168 +_ 21 169 + 17 170 _+ 24 169 _+ 16 0.77 
QRS complex duration (ms)* 101 + 17 102 ~ 15 101 _+ 14 1(12 +_ 14 0.91 
QT interval corrected for heart 441 + 25 439 +_ 27 439 _+ 41 435 _+ 27 0.71 
rate (ms) 
Data are presented as mean value + 1 SD. The four groups are compared using analysis of variance for repeated 
measures or (*) Friedman two-way analysis of variance. 
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The association between postinfarction arrhythmic events and 
cardiac autonomic impairment has been documented in clini- 
cal investigations (1-5). Moreover, experimental studies (22) 
showed that sympathetic hyperactivity promotes the occur- 
rence of life-threatening ventricular tachyarrhythmias, whereas 
augmented vagal tone has a protective antifibrillatory effect 
(7,8). Therefore, manipulation of cardiac autonomic function 
could induce a favorable change in the electrophysiologic 
milieu of the heart. Treatment with thrombolysis and reperfu- 
sion, as well as angiotensin-converting enzyme inhibitors, 
probably has a beneficial effect on sympathovagal balance after 
myocardial infarction (23-26), and beta-adrenergic blockade 
has been clearly shown (6) to improve survival in postinfarction 
patients. Nevertheless, a useful alternative approach may be to 
increase parasympathetic activity by means of vagal stimula- 
tion, especially because of its modest negative inotropic effect 
(8). 
Effects of oral pirenzepine on cardiac autonomic function 
after acute myocardial infarction. Wellstein and Pitschner (9) 
found that low doses of intravenous pirenzepine may increase 
the SD of the RR intervals by 58% in normal volunteers, 
suggesting the possibility of a cardiac vagomimetic intervention 
by means of this drug. Because their observation i  healthy 
young adults would not necessarily predict results in older 
subjects with myocardial infarction, we performed the present 
investigation. We found a significant increase in time and 
frequency domain measures of heart rate variability after 
administration oforal pirenzepine. Pirenzepine increased very 
low frequency power by 87% compared with placebo: this 
finding may have particular elevance because spectral mea- 
sures of heart rate variability in the very low and ultra low 
frequency bands eem to have a substantially higher prognostic 
power than that of the reduced vagal components (2). After 
pirenzepine treatment, the ratio of low frequency to high 
frequency spectral densities did not change significantly, and 
the increase in both low and high frequency powers was 
quantitatively similar. This is not surprising because the low 
frequency component reflects both parasympathetic and sym- 
pathetic nervous modulation (27). After pirenzepine, barore- 
ceptor reflex sensitivity was 60% higher than placebo values. 
Five patients with a baseline baroreceptor reflex sensitivity 
<4 ms/mm Hg showed an average increase of 61%, and three 
patients with a baseline sensitivity <3 ms/mm Hg showed an 
average increase of 67%. These data are similar to those 
provided by De Ferrari et al. (14) about autonomic effects of 
transdermal scopolamine, and they suggest hat pirenzepine 
modulation isalso present in patients at high risk of malignant 
ventricular arrhythmias (i.e., baroreceptor reflex sensitivity 
<3 ms/ram Hg) (4,5,13). 
The mechanism underlying the cholinomimetic effect of low 
doses of antimuscarinic agents has not been fully explained. It 
may result from the blockade of cardiac presynaptic M 1 
receptors that interrupts a negative auto feedback mechanism 
(9). Wellstein and Pitschner (9) suggest that acetylcholine 
could inhibit its own release through the activation of M 1 
receptors. Because M1 receptors have a higher affinity for 
antimuscarinic drugs than does the postsynaptic M2 subtype 
(9), low concentrations of pirenzepine could preferentially 
bind to them, leaving the M 2 receptors available for higher 
levels of acetylcholine for any level of neural activation. 
Anti-ischemic effect of pirenzepine. Marracini et al. (28) 
recently found in patients with effort myocardial ischemia that 
intravenous pirenzepine may significantly increase exercise 
tolerance over that achieved with saline solution. In their 
study, time to ischemia nd rate-pressure product of ischemia 
were significantly increased by pirenzepine, and the anti- 
ischemic effect of pirenzepine was similar to that induced by 
their reference drug, intravenous i osorbide dinitrate. Whether 
the oral dose of pirenzepine used to modulate cardiac auto- 
nomic function could also induce an anti-ischemic effect is yet 
to be demonstrated. However, myocardial ischemia nd sym- 
pathovagal impairment may be involved in the occurrence of a 
malignant ventricular tachyarrhythmia (21); therefore, the data 
of Marracini and coworkers, which complement our findings, 
may have interesting clinical implications. 
Pharmacologic modulation of cardiac autonomic function 
after acute myocardial infarction: oral pirenzepine and trans- 
dermal scopolamine. Recent studies (12-16) found that trans- 
dermal scopolamine may improve measures of both tonic and 
reflex cardiac vagal outflow after myocardial infarction and in 
patients with congestive heart failure. In the present investiga- 
tion we compared the effects of oral pirenzepine on heart rate 
variability and baroreceptor reflex sensitivity with those in- 
duced by transdermal scopolamine. The data showed that the 
two drugs had a similar cholinomimetic power in postinfarc- 
tion patients, but the overall incidence of adverse ffects was 
higher during treatment with scopolamine than with pirenz- 
epine. 
Concerning pharmacologic vagomimetic interventions in 
postinfarction patients, only few data about short-term treat- 
ment with transdermal scopolamine are available (12-15). 
Recently, at our institution, we interrupted a study planned to 
assess efficacy and safety of transdermal scopolamine after 
myocardial infarction on a mid-term treatment owing to the 
high incidence of adverse ffects (unpublished ata). Of five 
patients randomized to transdermal scopolamine, four (80%) 
had to be withdrawn from therapy within the 1st month of 
treatment. Two patients developed intractable cutaneous ery- 
thema in the site of patch application, and the other two 
reported blurred vision and drowsiness. As recommended by 
the manufacturer, the transdermal patch of scopolamine is
usually applied behind an ear, where the therapeutic system is 
able to deliver the programmed dose of the drug on the basis 
of the local cutaneous temperature and blood flow (29). 
However, because the small area available for the patch 
application may facilitate the occurrence of cutaneous rash, 
oral administration of pirenzepine may be preferable for 
long-term treatment. No patient in our study reported blurred 
vision or drowsiness during pirenzepine treatment, whereas 
three patients reported these effects during scopolamine ther- 
apy. Thus, oral pirenzepine seems to be better tolerated than 
transdermal scopolamine, a factor that may be relevant in 
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evaluating the feasibility of the clinical use of muscarinic 
receptor blockers after myocardial infarction. 
Study limitations. Our study has several limitations. 
1) Given the relatively low risk profile of our patient group and 
the small sample size, we cannot describe the effects of 
pirenzepine on patients who have a larger infarct size and a 
lower left ventricular ejection fraction. 2) Our patients were 
exposed to pirenzepine for only 3 days, and we have not 
assessed whether the vagomimetic modulation produced by 
pirenzepine may be maintained over a period of months. 
3) The fact that our study was not performed in double-blind 
fashion may represent a possible bias of our investigation. 
Conclusions and clinical implications. We have shown 
that low doses of oral pirenzepine may induce a sustained 
improvement in those autonomic indexes that predict a poor 
arrhythmic outcome after acute myocardial infarction (1-5). 
This finding suggests hat oral pirenzepine could have relevant 
therapeutic potential for the prophylaxis of postinfarction 
malignant ventricular arrhythmias. The cholinomimetic power 
of oral pirenzepine is similar to that of transdermal scopol- 
amine, which was recently found (12-15) to increase tonic and 
reflex cardiac vagal activity in survivors of an acute myocardial 
infarction; however, pirenzepine seems to be better tolerated 
than scopolamine. Whether the effects of oral pirenzepine on 
cardiac vagal outflow can improve survival in postinfarction 
patients remains to be assessed. However, the finding that 
pharmacologic vagal stimulation by means of oral pirenzepine 
is feasible and well tolerated may warrant further studies in the 
evaluation of new therapeutic approaches to preventing life- 
threatening ventricular arrhythmias after acute myocardial 
infarction. 
We are indebted to Cinzia Guicciardi, RN for expert echnical assistance and to 
Giovanni B. Migliori, MD for useful comments. 
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